Compare BOLT & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOLT | HKPD |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.6M |
| IPO Year | 2021 | 2025 |
| Metric | BOLT | HKPD |
|---|---|---|
| Price | $7.01 | $0.82 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 25.7K |
| Earning Date | 11-12-2025 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,195,000.00 | ★ $20,313,818.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $4.41 | $0.68 |
| 52 Week High | $10.50 | $2.76 |
| Indicator | BOLT | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 54.28 |
| Support Level | $6.14 | $0.76 |
| Resistance Level | $6.60 | $0.86 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 77.36 | 87.87 |
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.